UPDATE 2-J&J forecasts weak annual profit, misses revenue estimates
UPDATE 2-J&J forecasts weak annual profit, misses revenue estimates
(Adds details on drug sales, shares, background)
(添加有關藥品銷售、股票、背景的詳細信息)
Jan 22 (Reuters) - Johnson & Johnson on Wednesday forecast full-year profit largely below expectations, after posting a rare miss on quarterly revenue as sales of some of its major drugs fell short of Wall Street expectations.
路透1月22日電-強生週三預測全年利潤大幅低於預期，此前該公司公佈了罕見的季度營收下滑，原因是該公司一些主要藥物的銷售額低於華爾街預期。
Shares of the healthcare giant, which were trading at a record high prior to the results, fell about 1.5% to $147 in premarket trading.
這家醫療保健巨頭的股價在盤前交易中下跌約1.5%，至147美元。業績公佈前，該公司股價創下歷史新高。
J&J's pharmaceuticals unit, which makes up half of the overall sales and produces blockbuster drugs such as Imbruvica and Stelara, has powered much of the company's recent growth even as it works to improve the performance of its medical device and consumer health units.
強生的製藥部門佔總銷售額的一半，生產Imbrovica和Stelara等重磅炸彈藥物。儘管該公司正在努力改善其醫療設備和消費者健康部門的表現，但該部門在很大程度上推動了該公司最近的增長。
However, intense competition for some off-patent drugs such as prostate cancer drug Zytiga, coupled with pressure on prescription drug prices in the United States, has weighed on revenue at the top-earning unit.
然而，前列腺癌藥物Zytiga等一些非專利藥物的激烈競爭，加上美國處方藥價格的壓力，拖累了這家收入最高的部門的收入。
Revenue at the pharma unit, which also makes antidepressant Spravato and plaque psoriasis drug Tremfya, rose 3.5% to $10.55 billion in the fourth quarter, but missed the average estimate of $10.63 billion, according to two analysts polled by Refinitiv.
據Refinitiv調查的兩位分析師稱，製藥部門第四季度營收增長3.5%，至105.5億美元，但低於106.3億美元的平均預期。製藥部門還生產抗抑鬱藥Spravato和斑塊型牛皮癬藥物Tremfya。
Sales of psoriasis drug Stelara rose 17.7% to $1.70 billion, missing Credit Suisse's estimate of $1.79 billion. Cancer drug Imbruvica's sales rose 24.5% to $875 million, although they missed the brokerage's estimate of $907 million.
治療牛皮癬的藥物Stelara的銷售額增長17.7%，至17億美元，低於瑞士信貸17.9億美元的預期。抗癌藥物Imbrovica的銷售額增長24.5%，至8.75億美元，儘管低於該經紀公司預計的9.07億美元。
Medical device sales fell to $6.63 billion from $6.67 billion, also missing the average estimate of $6.69 billion according to Refinitiv data.
根據Refinitiv的數據，醫療器械銷售額從66.7億美元降至66.3億美元，也低於66.9億美元的平均預期。
The company said it expects full-year 2020 adjusted earnings per share in the range $8.95 to $9.10, with the top end of the range meeting analysts' average estimate.
該公司表示，預計2020年全年調整後每股收益在8.95美元至9.10美元之間，區間的高端符合分析師的平均預期。
Litigation expenses fell to $264 million in the fourth quarter, from $1.29 billion a year ago.
第四季度訴訟費用從去年同期的12.9億美元降至2.64億美元。
J&J's net earnings rose to $4.01 billion, or $1.50 per share, in the quarter, from $3.04 billion, or $1.12 per share, a year earlier.
強生當季淨利增至40.1億美元，合每股1.50美元，上年同期為30.4億美元，合每股1.12美元。
Excluding items, it earned $1.88 per share, beating the average analyst estimate by a cent, according to IBES data from Refinitiv.
根據Refinitiv的IBES數據，剔除項目，該公司每股盈利1.88美元，比分析師平均預期高出1美分。
Total sales rose 1.7% to $20.75 billion, below the average estimate of $20.80 billion. That was the company's first revenue miss in at least eight quarters. (Reporting by Manas Mishra and Saumya Sibi Joseph in Bengaluru Editing by Saumyadeb Chakrabarty)
總銷售額增長1.7%，至207.5億美元，低於208億美元的平均預期。這是該公司至少八個季度以來首次出現營收下滑。(Manas Mishra和Saumya Sibi Joseph在孟加盧市編輯Saumyadeb Chakrabarty報道)
譯文內容由第三人軟體翻譯。